Literature DB >> 19995186

The role of furin in papillomavirus infection.

Patricia M Day1, John T Schiller.   

Abstract

Papillomaviruses represent a medically important virus family. Infection with a high-risk human papillomavirus type is a prerequisite for cervical carcinoma development. Infection by low-risk types may result in the generation of benign skin warts. It was recently found that infectious entry of these viruses is dependent upon a specific proteolytic event that occurs prior to viral endocytosis. Specifically, a proprotein convertase, furin or proprotein convertase 5/6, must cleave the minor capsid protein for infection to proceed. Here, an overview of what is currently known about this process is presented, and what we have learned about the papillomavirus lifecycle from these studies discussed. This work also has implications for further advances in papillomavirus vaccine development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995186      PMCID: PMC2829937          DOI: 10.2217/fmb.09.86

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  47 in total

Review 1.  Papillomaviruses in human cancers.

Authors:  H zur Hausen
Journal:  Proc Assoc Am Physicians       Date:  1999 Nov-Dec

Review 2.  Lateral organization of membrane proteins: tetraspanins spin their web.

Authors:  Stéphanie Charrin; François le Naour; Olivier Silvie; Pierre-Emmanuel Milhiet; Claude Boucheix; Eric Rubinstein
Journal:  Biochem J       Date:  2009-05-13       Impact factor: 3.857

3.  Human papillomavirus infection requires cell surface heparan sulfate.

Authors:  T Giroglou; L Florin; F Schäfer; R E Streeck; M Sapp
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.

Authors:  Y Kawana; K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

6.  Directed actin polymerization is the driving force for epithelial cell-cell adhesion.

Authors:  V Vasioukhin; C Bauer; M Yin; E Fuchs
Journal:  Cell       Date:  2000-01-21       Impact factor: 41.582

7.  Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

Authors:  Katherine M Johnson; Rhonda C Kines; Jeffrey N Roberts; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Secretory proprotein convertases PACE4 and PC6A are heparin-binding proteins which are localized in the extracellular matrix. Potential role of PACE4 in the activation of proproteins in the extracellular matrix.

Authors:  Akihiko Tsuji; Kensuke Sakurai; Emi Kiyokage; Takahito Yamazaki; Sizuyo Koide; Kazunori Toida; Kazunori Ishimura; Yoshiko Matsuda
Journal:  Biochim Biophys Acta       Date:  2003-01-31

9.  Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.

Authors:  Patricia M Day; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

10.  Establishment of human papillomavirus infection requires cell cycle progression.

Authors:  Dohun Pyeon; Shane M Pearce; Simon M Lank; Paul Ahlquist; Paul F Lambert
Journal:  PLoS Pathog       Date:  2009-02-27       Impact factor: 6.823

View more
  37 in total

1.  Inhibition of gamma secretase blocks HPV infection.

Authors:  Hao-Shun Huang; Christopher B Buck; Paul F Lambert
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

Review 2.  Human papillomavirus molecular biology.

Authors:  Mallory E Harden; Karl Munger
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-05       Impact factor: 5.657

Review 3.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

4.  Mucin biopolymers as broad-spectrum antiviral agents.

Authors:  Oliver Lieleg; Corinna Lieleg; Jesse Bloom; Christopher B Buck; Katharina Ribbeck
Journal:  Biomacromolecules       Date:  2012-05-21       Impact factor: 6.988

5.  Incoming human papillomavirus type 16 genome resides in a vesicular compartment throughout mitosis.

Authors:  Stephen DiGiuseppe; Wioleta Luszczek; Timothy R Keiffer; Malgorzata Bienkowska-Haba; Lucile G M Guion; Martin J Sapp
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-17       Impact factor: 11.205

Review 6.  Second-generation prophylactic HPV vaccines: successes and challenges.

Authors:  Mitchell Tyler; Ebenezer Tumban; Bryce Chackerian
Journal:  Expert Rev Vaccines       Date:  2013-12-18       Impact factor: 5.217

7.  Opposing effects of bacitracin on human papillomavirus type 16 infection: enhancement of binding and entry and inhibition of endosomal penetration.

Authors:  Samuel K Campos; Janice A Chapman; Martin J Deymier; Matthew P Bronnimann; Michelle A Ozbun
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

8.  A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection.

Authors:  Matthew P Bronnimann; Janice A Chapman; Chad K Park; Samuel K Campos
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

10.  Efficient delivery of DNA vaccines using human papillomavirus pseudovirions.

Authors:  S Peng; A Monie; T H Kang; C-F Hung; R Roden; T-C Wu
Journal:  Gene Ther       Date:  2010-07-29       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.